3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
51
Recruiting
5
Terminated
2
Active not recruiting
2
Withdrawn
1
Unknown
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Conditions
Sarcoma
60
Gliosarcoma
19
Glioblastoma
19
Osteosarcoma
15
Lymphoma
14
Central Nervous System Neoplasms
13
Dendritic Cell Sarcoma, Interdigitating
11
Rhabdomyosarcoma
10
Oligodendroglioma
10
Neuroblastoma
10
Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Brain Neoplasms
10
Bone Neoplasms
10
Astrocytoma
10
Recurrence
9
Breast Neoplasms
9
Sarcoma, Ewing
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Non-Hodgkin
8
Liposarcoma
8
Glioma
8
Burkitt Lymphoma
8
Wilms Tumor
7
Neoplasm Metastasis
7
Melanoma
7
Hodgkin Disease
7
Gastrointestinal Stromal Tumors
7
Ovarian Neoplasms
6
Medulloblastoma
6
Interventions
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Acquired Immunodeficiency Syndrome
×
Sarcoma
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn